BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26270625)

  • 1. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
    Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
    Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
    Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
    J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
    Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
    Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
    Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
    Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
    J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How the direct oral anticoagulant apixaban affects thrombin generation parameters.
    Tripodi A; Padovan L; Veena C; Scalambrino E; Testa S; Peyvandi F
    Thromb Res; 2015 Jun; 135(6):1186-90. PubMed ID: 25895845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.
    Helin TA; Virtanen L; Manninen M; Leskinen J; Leppilahti J; Joutsi-Korhonen L; Lassila R
    J Thromb Thrombolysis; 2017 May; 43(4):562-569. PubMed ID: 28315166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
    Levi M; Moore KT; Castillejos CF; Kubitza D; Berkowitz SD; Goldhaber SZ; Raghoebar M; Patel MR; Weitz JI; Levy JH
    J Thromb Haemost; 2014 Sep; 12(9):1428-36. PubMed ID: 24811969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.
    Pfrepper C; Behrendt LC; Bönigk H; Siegemund T; Metze M; Franke D; Petros S; Siegemund A
    Int J Lab Hematol; 2022 Feb; 44(1):193-201. PubMed ID: 34585540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.
    Nagalla S; Thomson L; Oppong Y; Bachman B; Chervoneva I; Kraft WK
    Clin Transl Sci; 2016 Jun; 9(3):176-80. PubMed ID: 27170068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
    Weitz JI; Segers A; Raskob G; Roberts RS; Francis C; Lassen MR; Fuji T; Swaim RM; Lee M; Peters G; DiBattiste PM; Tesfaye F; Strony J
    J Thromb Haemost; 2019 Dec; 17(12):2081-2088. PubMed ID: 31529590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.
    Brinkman HJM; Zuurveld M; Meijers JCM
    Res Pract Thromb Haemost; 2022 Jul; 6(5):e12775. PubMed ID: 35928523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.